GUJTHEMGujarat Themis Biosyn Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India and Japan. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 17.2% YoY
- • ROE: 17.4%
- • Debt/Equity: 0.56
- • RSI: 57
- • MACD: bullish
- • Price vs EMA21: above
- • Pullback to 21-EMA signal (setup quality 80%)
Bull case
- • Revenue growth: 17.2% YoY
- • ROE: 17.4%
- • Debt/Equity: 0.56
- • RSI: 57
Bear case
- • Profit growth: -9.1% YoY
- • Valuation vs sector: P/E 98.5 vs sector 40.5
- • Volume: 0.5x 20-day average
- • Volatility: 51% annualized
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Profit growth: -9.1% YoY
- • Valuation vs sector: P/E 98.5 vs sector 40.5
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹21.01). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.